Pharmaceutical industry-sponsored meals and prescriptions of biologics for asthma

Letter Allergy

Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic

Anju Murayama et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2022)

Article Infectious Diseases

Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020

Anju Murayama et al.

Summary: This study aimed to evaluate the trend in nonresearch payments made by the industries to infectious disease physicians in the United States since the launch of the Open Payments Database and during the COVID-19 pandemic. The results showed a decrease in the total amount of payments and the number of physicians accepting payments since the inception of the database, and a significant decrease in nonresearch payments due to the pandemic. However, there was a slight increase in payments and the number of physicians accepting payments after the onset of the pandemic.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Review Medicine, General & Internal

Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? A Systematic Review

Aaron P. Mitchell et al.

Summary: The study found that financial payments from the drug industry to U.S. physicians are associated with physician prescribing practices, including increased prescribing of the paying company's drug, increased prescribing costs, and increased prescribing of branded drugs.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Review Allergy

How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit

Amber N. Pepper et al.

Summary: Five biologic medications approved for treating uncontrolled asthma target elevated type 2 inflammatory markers like eosinophils, nitric oxide, or IgE. Factors such as asthma severity, biomarkers, and treatment goals should guide initial biologic choice, with shared decision-making with patients to optimize adherence. Monitoring response and troubleshooting are essential for patients with suboptimal responses, with potential need for changing biologic therapy or exploring other treatment options.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States

Kosuke Inoue et al.

Summary: The study found that marketing payments related to PCSK9i received by physicians in 2016 were associated with an increase in PCSK9i prescriptions filled in 2017, especially among primary care physicians.

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2021)

Add to Collection

Article Allergy